ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,783.00
0.00%
S&P ASX All Technology
3,113.80
0.00%
Brent Oil
84.47
0.34%
US Dollar vs AUD
1.50466
-0.02%
Bitcoin
60,849.60
-1.56%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Crossject (ALCJ)

  7. Crossject (ALCJ) News

ALCJ

Crossject (ALCJ)

Crossject
Date:
Sort by:
 Showing the most relevant articles for your search:EU:ALCJ
DateTimeSourceHeadlineSymbolCompany
26/06/202415:30GlobeNewswire Inc.Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence studyEU:ALCJCrossject
26/06/202415:30GlobeNewswire Inc.Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence studyEU:ALCJCrossject
26/06/202415:30GlobeNewswire Inc.Crossject met en perspective le potentiel de ZEPIZURE® à la lumière de l'étude de référence RAMPART et de sa propre étude de bioéquivalence récemment publiée.EU:ALCJCrossject
18/06/202420:30GlobeNewswire Inc.Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital socialEU:ALCJCrossject
13/06/202417:36GlobeNewswire Inc.Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital socialEU:ALCJCrossject
12/06/202415:30GlobeNewswire Inc.Crossject appoints Dan Chiche, MD as Chief Medical Officer North AmericaEU:ALCJCrossject
12/06/202415:30GlobeNewswire Inc.Crossject appoints Dan Chiche, MD as Chief Medical Officer North AmericaEU:ALCJCrossject
12/06/202415:30GlobeNewswire Inc.Crossject nomme Dan Chiche, MD au poste de Directeur Médical Amérique du NordEU:ALCJCrossject
05/06/202403:30GlobeNewswire Inc.Crossject announces highly successful closing of its €8 million rights offeringEU:ALCJCrossject
05/06/202403:30GlobeNewswire Inc.Crossject announces highly successful closing of its €8 million rights offeringEU:ALCJCrossject
05/06/202403:30GlobeNewswire Inc.Crossject annonce le vif succès de son augmentation de capital de 8 millions d’eurosEU:ALCJCrossject
30/05/202418:30GlobeNewswire Inc.Crossject annonce la publication de données cliniques sur ZEPIZURE® dans Neurology and TherapyEU:ALCJCrossject
30/05/202418:30GlobeNewswire Inc.Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and TherapyEU:ALCJCrossject
30/05/202418:30GlobeNewswire Inc.Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and TherapyEU:ALCJCrossject
03/05/202401:30GlobeNewswire Inc.Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in EuropeEU:ALCJCrossject
03/05/202401:30GlobeNewswire Inc.Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in EuropeEU:ALCJCrossject
03/05/202401:30GlobeNewswire Inc.Crossject signe une extension géographique de l'accord de commercialisation de ZEPIZURE® en EuropeEU:ALCJCrossject
01/05/202403:05GlobeNewswire Inc.Crossject annonce le lancement d’une augmentation de capitalEU:ALCJCrossject
25/04/202415:32GlobeNewswire Inc.Crossject reports audited financial results for 2023EU:ALCJCrossject
25/04/202415:32GlobeNewswire Inc.Crossject reports audited financial results for 2023EU:ALCJCrossject
25/04/202415:32GlobeNewswire Inc.Crossject communique ses résultats financiers audités pour 2023EU:ALCJCrossject
11/04/202400:30GlobeNewswire Inc.Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital socialEU:ALCJCrossject
03/04/202403:35GlobeNewswire Inc.Crossject trading on Euronext to resume as usual on Wednesday April 3EU:ALCJCrossject
03/04/202403:35GlobeNewswire Inc.La cotation sur l’action de Crossject à Euronext reprendra comme d’habitude le mercredi 3 avrilEU:ALCJCrossject
02/04/202419:30GlobeNewswire Inc.Crossject advances in its U.S. Strategy and reports Financial Results for 2023EU:ALCJCrossject
02/04/202419:30GlobeNewswire Inc.Crossject advances in its U.S. Strategy and reports Financial Results for 2023EU:ALCJCrossject
02/04/202419:30GlobeNewswire Inc.Crossject poursuit sa stratégie de développement aux États-Unis et publie ses résultats financiers pour 2023EU:ALCJCrossject
08/03/202417:30GlobeNewswire Inc.Crossject gender equality score reaches 96/100 in 2024EU:ALCJCrossject
08/03/202417:30GlobeNewswire Inc.Le Score de l’index Egalité femmes-hommes chez Crossject atteint 96/100 en 2024EU:ALCJCrossject
08/03/202417:30GlobeNewswire Inc.Crossject gender equality score reaches 96/100 in 2024EU:ALCJCrossject
 Showing the most relevant articles for your search:EU:ALCJ

Your Recent History

NYSE
MRK
Merck
ASX
RIO
Rio Tinto
COIN
BTCUSD
Bitcoin
NYSE
MCD
McDonalds
ASX
XAO
Australian SE All Ordina...
NASDAQ
GOOGL
Alphabet
ASX
WES
Wesfarmers
FX
AUDCAD
AUD vs CAD
ASX
XTO
S&P ASX 100
ASX
BHP
BHP
CCOM
SILVER
SILVER
FX
AUDJPY
AUD vs Yen
ASX
ANZ
Australia And New Zealan...
NASDAQ
TSLA
Tesla
ASX
MQG
Macquarie
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved